Kornimate/medical-research-clean huggingface dataset:
investigating the diagnostic potential of tear proteins in cancer - a pilot study

Conditions: Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Melanoma

Summary: this pilot study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.

the pilot study is an observational study to investigate the diagnostic potential of tear proteins for breast, ovarian, prostate, melanoma, pancreatic, and colon cancer. in this pilot study, we use lacrimal gland fluid (tears) as a liquid biopsy source for investigating the protein repertoire and conducting biomarker discovery studies with a goal to develop new tear-based tests that can detect crucial cancer-related biomarkers in the pan-cancer types. proteomic studies on tears have shown to express between 500-1500 proteins with \~35% overlap with serum proteome. the easy accessibility of tear fluid with minimal post-processing procedures and better access to lower molecular weight proteins make tears an ideal source to identify commonly associated cancer biomarkers. additionally, the results from this study will aid in improving our understanding of the cancer types and commonalities that exist between them.

Eligibility criteria:
inclusion criteria: * 18-100 years of age * presenting for the evaluation of an abnormal exam or test (mammogram, ultrasound, mri, pet, etc.) * presenting for the evaluation of a palpable lump or mass * presenting with a mass may be pre or post-biopsy/diagnostic as long as there is a portion of the mass remaining. * have been diagnosed but have not received treatment exclusion criteria: * less than 18 years of age or more than 100 years of age * concurrent eye infection or trauma * acute conjunctivitis

Keywords: preventative screening protein biomarkers lacrimal tear fluid non-invasive tear collection clia laboratory affordable proteomics metabolomics protein microarray elisa assay
riluzole augmentation in treatment-refractory obsessive-compulsive disorder

Conditions: Obsessive-compulsive Disorder; Ocd

Summary: obsessive-compulsive disorder (ocd) affects 2-3% of the population and leads to a great deal of suffering. many patients benefit from established treatments, the mainstay of which are cognitive behavioral therapy and a group of antidepressant medications known as serotonin reuptake inhibitors. however, 20-30% of patients get minimal benefit from these established therapeutic strategies. new avenues of treatment are urgently needed. existing medications for obsessive-compulsive disorder affect the neurotransmitters serotonin or dopamine; but increasing evidence suggests that functional disruptions of a different neurotransmitter, glutamate, may contribute to some cases of ocd. the investigators are therefore interested in using medications that target glutamate as novel treatment options for those ocd patients who do not benefit from established treatments. one such medication is the drug riluzole, which is fda approved for amyotrophic lateral sclerosis (als), or lou gehrig's disease, but may be of benefit to patients with psychiatric disorders due to its ability to moderate excessive glutamate. in preliminary studies, in which the investigators treated patients with riluzole (in addition to their established pharmacological regimen) in an open-label fashion (that is, without a placebo-treated control group), the investigators have found about 40-50% of patients to substantially improve over 2-3 months. while immensely promising, these preliminary studies do not prove riluzole is truly a new beneficial medication for the treatment of ocd; a more rigorous placebo-controlled trial is needed for that purpose. the investigators are therefore now recruiting patients to participate in a double-blind, placebo-controlled trial of riluzole, added to whatever other ocd medications they are taking.


Eligibility criteria:
inclusion criteria: * diagnostic and statistical manual of mental disorders iv (dsm-iv) diagnosis of ocd, confirmed by structured clinical interview for dsm-iv (scid-iv); symptoms of at least 1 year duration * moderate to severe ocd symptoms as measured by a score on the yale-brown obsessive-compulsive scale (y-bocs) of 16 or greater * documented failure of an adequate trial of a selective serotonin reuptake inhibitor (ssri) * agreement to engage in a reliable form of birth control (women only) exclusion criteria: * primary diagnosis of a psychotic disorder * active substance abuse or dependence * unstable medical condition * prior exposure to riluzole * prior psychosurgery * pregnancy, breastfeeding, or intent to become pregnant during study * liver function tests (lfts) elevated to more than 2x the upper limit of normal * evidence of active liver disease * seizure disorder * active suicidal ideation

Keywords: obsessive-compulsive disorder ocd glutamate riluzole augmentation treatment
mims® retrospective chart review

Conditions: Open Angle Glaucoma

Summary: this is a post-market clinical follow-up, retrospective chart review of mims® surgical procedures conducted during time period between sep 2023 and may 2025.


Eligibility criteria:
inclusion criteria: 1. eye treated with mims® device as a standalone procedure 2. mims® surgery was performed between 27 sep 2023 and 30 april 2024

Keywords: polypharmacy intraocular pressure mims minimally invasive glaucoma surgery migs mtmt trabeculectomy sclerostomy
study of pet imaging with 18f-tfb in patients with thyroid cancer

Conditions: Thyroid Cancer

Summary: the goal of the study is to evaluate a new imaging test that may allows the investigators to predict the uptake of radioactive iodine by thyroid cancer faster than the current standard and that does not interfere with the uptake of radioactive iodine used for therapy.


Eligibility criteria:
inclusion criteria: * patients must have histologically or cytologically confirmed thyroid carcinoma of follicular origin (including papillary and its respective variants). * patients should have tumors that are radiographically evident on pet, ultrasound, ct or mri * age ≥ 18 years. * ecog performance status ≤ 2 (or karnofsky ≥60%). * patients must have normal organ and bone marrow function as defined below: * absolute neutrophil count (anc) \> 1.5x10\^9/l * hemoglobin ≥ 9 g/dl * platelets ≥ 100 x 10\^9/l * albumin ≥ 2.5 g/dl * total bilirubin ≤ 1.5x institutional uln * aspartate aminotransferase (ast) and alanine aminotransferase (alt) ≤ 2x institutional uln unless it is related to the primary disease * creatinine ≤ 1.5 mg/dl or calculated creatinine clearance (cockcroft-gault formula) ≥ 50 ml/min or 24-hour urine creatinine clearance ≥ 50 ml/min * negative pregnancy test within 7 days prior to starting the study in premenopausal women. women of non-childbearing potential may be included without pregnancy test if they are either surgically sterile or have been postmenopausal for ≥ 1 year. * fertile men and women must use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician. effective methods of contraception are defined as those, which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices). at the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance. (periodic abstinence \[e.g., calendar, ovulation, symptothermal, postovulation methods\] and withdrawal are not acceptable methods of contraception.) * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements. * pregnant, lactating, or breast feeding women. * patients unable to follow a low iodine diet or requiring medication with high content in iodide (amiodarone). * patients who received iodinated intravenous contrast as part of a radiographic procedure within 3 months of study registration. those that have had iodinated intravenous contrast for ct imaging within this time frame may still be eligible if a urinary iodine analysis reveals that the excess iodine has been adequately cleared after the last intravenous contrast administration. * unwillingness or inability to comply with study procedures.

Keywords: pet imaging 18f-tfb 17-315
azithromycin for meibomian gland disease

Conditions: Dry Eye; Neuropathic Eye Pain; Ocular Microbiome; Depression, Anxiety

Summary: this study aims to elucidate the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to meibomian gland dysfunction.

this is a randomized, placebo-controlled, double masked trial of the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to meibomian gland dysfunction. dry eye syndrome (des) is a persistent feeling of ocular discomfort that encompasses dryness, irritation, foreign body sensation and burning. in the united states, it is the most common non-refractive cause of visits to eye care providers, and has been shown to have a significant impact on quality of life of patients who suffer from this condition. most common cause of des is meibomian gland disease (mgd). in the vast majority of cases, mgd is not binding, but rather causes persistant ocular discomfort. oral antibiotics, particularly the tetracyclines and macrolides, are frequently prescribed for the treatment of mgd. there is little good-quality evidence to support this practice. this study is designed to evaluate the effectiveness of oral azithromycin on patient-reported dry eye symptoms. concomitantly, we will also study the composition of the ocular surface microbiome in mgd, and its response for oral antibiotics.

Eligibility criteria:
inclusion criteria: * symptomatic meibomian gland disease, defined as patient-reported ocular surface symptoms such as dryness, grittiness, foreign body sensation, or eye fatigue in combination with clinically identifiable meibomian gland disease with grade 2 or greater involvement on the meibomian gland grading scale (section xv, item 2). * osdi score greater than or equal to 20 * ability to give informed consent exclusion criteria: * age less than 18 years * allergy or intolerance to oral azithromycin or topical dexamethasone * allergy or intolerance to the preservatives used in topical ophthalmic 0.1% dexamethasone: sodium bisulfite, phenylethyl alcohol, benzalkonium chloride * history of prolonged qt interval, history of torsades des pointes, congenital long qt syndrome, bradyarrhythmias, heart failure * patients currently taking medications that prolong the qt interval (table 1) * aqueous deficiency dry eye defined as schirmer's strip testing without anesthesia with £ 5mm of tears on two separate tests. * ocular surface inflammatory disease, including cicatrizing conjunctivitis, graft versus host disease, stevens johnson syndrome * atopic disease with ocular involvement * limbal stem cell deficiency * oral or topical ophthalmic antibiotic use within the last 90 days * oral prednisone use \>5mg per day * topical ophthalmic steroid use within the past 30 days * topical ophthalmic anti-inflammatory (including non-steroidal anti-inflammatory medications, lifitegrast, or cyclosporine) use within the past 30 days * patients who are currently pregnant, planning on becoming pregnant during the study period, or currently breastfeeding.
ceftriaxone in non-neutropenic fever

Conditions: Histiocytosis; Pediatric Patients With Cancer

Summary: this is a retrospective chart review of all patients cared for at monroe carell jr. children's hospital at vanderbilt including the following: * patients between 2007-2009 with malignancy, langerhans cell histiocytosis (lch) or hemophagocytic lymphohistiocytosis (hlh) and a central venous catheter who were under 23 years of age at time of diagnosis in order to ascertain the associated symptoms, management and outcome of all episodes of non-neutropenic fever. * to identify a subset of low-risk patients that can be safely managed without use of empiric antibiotics.


Eligibility criteria:
inclusion criteria: * diagnosed with malignancy, langerhans cell histiocytosis,or hemophagocytic lymphohistiocytosis from 2007 through 2010 * under 23 years at time of diagnosis of malignancy, langerhans cell histiocytosis,or hemophagocytic lymphohistiocytosis * treated at monroe carell jr. children's hospital at vanderbilt for aforementioned diagnosis from 2007 through 2012 * while on immunosuppressive therapy with a central venous line in place had at least one documented episode of fever (defined as ≥ 38.0°celsius orally for over 30 minutes or ≥ 38.3°celsius orally x1). exclusion criteria: * does not meet all inclusion criteria as stated above
double-blind, randomized, dose ranging study of alferon ldo (low dose oral interferon alfa-n3 (human leukocyte derived)) in hiv+ subjects

Conditions: HIV Infections

Summary: to conduct a double-blind, randomized, dose ranging study of an orally administered low dose interferon alfa-n3 (ifn-an3) immunomodulator in the treatment of symptomatic hiv+ subjects.


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * zidovudine (azt). * didanosine (ddi) patients must have: * seropositivity to hiv-1 by elisa and western blot. * at least 1 of the hiv-related clinical symptoms or opportunistic infections listed in protocol. * written informed consent. * if already on zidovudine (azt) or didanosine (ddi), must have been on this therapy for at least 75 of the 90 days prior to study entry. prior medication: allowed: * zidovudine (azt). * didanosine (ddi) exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * major active opportunistic infection requiring active care within 2 weeks of study entry. * evidence of chronic hepatitis with severe liver dysfunction: * albumin \ 5 x upper limit of normal prothrombin time \> 1.5 x upper limit of normal). * other active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular, neurologic, or psychiatric disorder. * transfusion dependency defined as requiring \> 1 unit of packed red blood cells (rbc) per month within 3 months prior to study entry. concurrent medication: excluded: * experimental medications other than didanosine (ddi). * chronic prophylactic use of any topical or systemic fungal medication such as ketoconazole, fluconazole, or clotrimazole. * chronic prophylactic use of any topical or systemic anti-viral medication such as acyclovir or ganciclovir except zidovudine (azt) or didanosine (ddi). patients with the following are excluded: * asymptomatic at study entry. * presence of antibodies to interferon due to prior therapy. * hospitalization within 2 weeks of study entry. * transfusion dependency. * unwilling or unable to give informed consent. * evidence of any concurrent organ dysfunction listed in exclusion co-existing conditions. * unlikely or unable to comply with the requirements of the protocol. prior medication: excluded within 6 weeks of study entry: * interferons. * excluded within 45 days of study entry: * immunosuppressive agents. * chemotherapy. * steroids. * immunomodulators. * isoprinosine. * bcg vaccine. prior treatment: excluded within 2 weeks of study entry: * hospitalization. active intravenous (iv) drug abuse.

Keywords: interferon type i
cell bank of epstein barr virus specific cytotoxic t lymphocytes

Conditions: EBV Associated Lymphoma

Summary: patients patients enrolled in this study have a lymphoma caused by ebv (after bone marrow transplantation, organ transplantation or patient immunodeficient. they will receive one to three injections of allogenic ctl specific ebv. the purpose of this study is to ensure that these injections can not cause a gvh and to study what the side effects are and to see whether this therapy might help patients with lymphoma. immunological monitoring will also be studied.


Eligibility criteria:
inclusion criteria: * male or female, without immunosuppressed organ transplant or immunocompromised and who received a kidney transplant, or kidney-pancreas, or heart or lung or heart-lung, or liver, or cells hematopoietic stem cells, and has given its consent * aged 18 to 75 years children aged more than 12 months, * ps \<4 * viral load determined ebv * life expectancy\> 1 month * patient typed for hla dp dq dr abc * patients with lymphoma in the immunosuppressed associated with ebv and failure, partial response (\<50%) or relapsed after treatment with monoclonal antibodies and / or chemotherapy completed for at least three weeks. patients with partial response may have a pet scan to confirm the lack of response. * patient with a measurable mass to assess the response or bone marrow infiltration and / or measurable blood and having frozen tumor material or having a repeat biopsy. * availability of a ctl matching at least two hla or one hla after validation experts with tumor cells * test de cytotoxicity negative exclusion criteria: * patient pregnant or lactating * concurrent infection with hiv * ebv negative lymphomas * if acute gvhd\> grade ii j-1 before injection (case grafts csh) * treatment of molecules in pre-marketing authorization older than 21 days * no matching at least two ctl hla or non expert validation for the use of ctl with hla sharing a single tumor * test of cytotoxicity positive * lack of recognition of tumor cells when available
understanding substance use and incident hiv/sti among young black msm

Conditions: HIV; Substance Abuse

Summary: the scientific purpose of this study is to look at how substance use may relate to human immunodeficiency virus (hiv) infection among young black men who have sex with men in atlanta.

young black men who have sex with men (ybmsm) are a critically at-risk population in the united states and atlanta that faces extremely high incidence rates of hiv and other sexually transmitted infections (stis). the understanding of what places this group of men at high risk is incomplete, and the role of substances in amplifying that risk is unclear. this study will fill a number of gaps about how substances and partnerships place ybmsm at increased hiv risk. the study includes several innovative aspects. first, the investigators are using a theoretical framework to understand multilevel associations between substance use and hiv risk behavior in ybmsm in the southeastern united states, a critically at-risk but understudied population. second, the investigators are using a variety of enhanced measurement methods to understand these associations. the investigators are supplementing self-reported substance use with objective measures to enhance the sensitivity of classifying recent use. the investigators will analyze incident hiv/sti endpoints in addition to self-reported sexual behaviors. the investigators will use detailed, event-based and dyadic measures of substance use and its covariates, which will capture both sexual and non-sexual contexts of use. although previous cohort studies have explored alcohol and drug use during sexual events among men who have sex with men (msm), few studies have described both sexual and non-sexual patterns of, and motivations for, substance use among ybmsm, and none have incorporated longitudinal biomarkers of substance use and related these to incident infection outcomes. finally, the investigators are using a mixed-methods approach to provide context to the quantitative findings. by recruiting subjects to a nested qualitative study within the larger cohort based on their interval-specific risks, the investigators will gain in-depth information regarding the emergence, persistence, and resolution of these complex relationships between substances and sexual risk behaviors among ybmsm and how these relationships emerge and are resolved over time.

Eligibility criteria:
inclusion criteria: * male at birth * currently identifies as male * age ≥18 years and \< 30 years at enrollment * had anal sex with a man in lifetime * has had any sex with a man in the past 3 months * self-reported race is black/african american * lives in atlanta area and plans to remain for 2 years * is able to complete the survey instruments in english * is willing to provide at least 2 means of contact * is willing to be re-contacted for the return of hiv/sti testing results, and for other study reasons as necessary * is not enrolled in an hiv prevention trial exclusion criteria: * self-reported multiple or non-black/african american race(s) * self-reported hispanic ethnicity * (for prospective follow-up) participant screens hiv-positive
randomized multicenter trial of prehospital initiated facilitated percutaneous coronary intervention (pci) versus primary pci in st-segment-elevation mi (stemi)

Conditions: Myocardial Infarction

Summary: prehospital initiated facilitation of primary percutaneous coronary intervention by fibrinolysis might be helpful in re-opening the infarct related artery prior to percutaneous coronary intervention. this studies tests the hypothesis that prehospital initiated facilitated pci is superior to primary percutaneous coronary intervention with respect to infarct size.

patients with stemi with symptoms \< 3 hours are randomized in the region of leipzig to either prehospital full-dose fibrinolysis (+asa, clopidogrel and heparin) with subsequent facilitated percutaneous coronary intervention or to primary percutaneous coronary intervention (after asa + heparin + clopidogrel). patients undergo cardiac magnetic resonance for assessment of infarct size early at day 1-4 after randomization.

Eligibility criteria:
inclusion criteria: * angina pectoris \< 3 hours * st-elevation myocardial infarction exclusion criteria: * active bleeding * active gastric ulcus * previous stroke * uncontrolled hypertension (\> 200 mmhg) * cerebral surgery \< 8 weeks * major surgery \< 4 weeks * malignancy * treatment with coumarines * pregnancy

Keywords: infarction facilitated pci primary pci infarct size fibrinolysis st-elevation myocardial infarction (stemi)
accuracy of endoscopists in predicting polyp pathology

Conditions: Resected Polyp

Summary: the study purpose is to assess the accuracy of experienced endoscopists at a community hospital in predicting histological types of polyps resected at colonoscopy using white light. patients 50 years or older undergoing first-time screening colonoscopy will be included in this observational study.

the study purpose is to assess the accuracy of experienced endoscopists at a community hospital in predicting histological types of polyps resected at colonoscopy using white light. the study will be conducted at good samaritan hospital and trihealth surgery center west. study participants include patients 50 years or older undergoing first-time screening colonoscopy. this is an observational study and does not involve any patient interventions. after completing the colonoscopy, the endoscopist will document their prediction of the polyp type. the polyp type predicted by the endoscopist will be compared to the polyp type documented in the pathology report to determine accuracy. it is estimated that study enrollment will take 6 months.

Eligibility criteria:
inclusion criteria: * males and females exclusion criteria: * first degree relative diagnosed with colorectal carcinoma at age 59 or under * new onset of iron deficiency anemia (within past 3 months) * abnormal imaging of colon within past 3 months * pregnant women * inadequate visualization reported by endoscopist

Keywords: colonoscopy, polyp, endoscopist